Innovent Biologics Inc

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for the treatment of non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for the treatment of ocular fundus disease; IBI-303, an adalimumab biosimilar for the treatment of autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it is involved in the development of IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung cancer, esophageal cancer, gastric cancer, and Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for the treatment of advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib in China; and a strategic alliance with Eli Lilly and Company, and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.